Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

424 results about "Cell targeting" patented technology

Target cell. n. 1. A cell selectively affected by a particular agent, such as a virus, drug, or hormone.

Multifunctional proteolysis-targeting chimera conjugates

The present invention relates to various molecular constructs having at least one cellular-targeting element, one protein-targeting element, and one ubiquitin ligase recruitment element, wherein these elements are conjugated in a manner that facilitates cellular uptake and targeted degradation of specific proteins within cells. The present invention further relates to multifunctional proteolysis-targeting chimera conjugates and uses thereof for the treatment of diseases or disorders such as immune and inflammatory diseases, infectious diseases, cardiovascular diseases, endocrine disorders, and various cancers that are otherwise resistant to traditional therapeutic regimens.
Owner:BIOXEL INC

Stealth lipid nanoparticle compositions for cell targeting

The present disclosure provides bispecific stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., immune effector cells such as T cells, B cells, natural killer cells, and dendritic cells, to modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.
Owner:GENERATION BIO CO

Dual mode 18F-labelled theranostic compounds and uses thereof

A compound or molecular complex. The compound or molecular complex comprises: a metal chelator configured for chelation with a radioactive isotope or a non-radioactive isotope; and a trifluoroborate (BF3)-containing moiety configured for 19F / 18F exchange or a precursor thereof; and optionally a cell-targeting domain.
Owner:THE UNIV OF BRITISH COLUMBIA +1

Mutant AAV with central nervous system targeting motifs and compositions containing same

Provided herein are compositions including brain, brain microvascular endothelial cell-targeting peptides and / or blood-brain barrier crossing (BBB) tissue-targeting peptides linked thereto or inserted in a targeting protein of a recombinant vector having at least one exogenous peptide comprising Xn – n-mer – Xm. Compositions providing such conjugates, targeting peptides, or recombinant vectors having an engineered capsid or envelope protein are provided as are uses thereof.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA

E3 ubiquitin enzyme mutant, modification and protein targeted degradation system thereof and application of E3 ubiquitin enzyme mutant

The invention discloses an E3 ubiquitin enzyme mutant as well as modification and a protein targeted degradation system and application thereof, and particularly relates to a series of targeted protein degradation enhanced E3 ubiquitin enzymes (Trim21-N) and a modification method thereof, the E3 ubiquitin enzymes (Trim21-N) are obtained by modifying a wild type Trim21 (wtTrim21) protein structural domain, and the E3 ubiquitin enzymes comprise Trim21-a, Trim21-b, Trim21-c, Trim21-d, Trim21-e and Trim21-f. The efficiency of degrading the target protein through the ubiquitin proteasome is remarkably improved, and the method has the characteristics of strong endogenous and exogenous universality, high specificity, ubiquitin proteasome dependence, low cytotoxicity, strong cell compatibility and the like on the degradation of the target protein. The invention provides E3 ubiquitin enzyme (Trim21-N) based on a targeted protein degradation enhancement version and an exogenous fluorescence report degradation system of the E3 ubiquitin enzyme (Trim21-N), preferably Trim21-e with the optimal degradation effect, and the E3 ubiquitin enzyme (Trim21-N) is named as delta Trim21. The invention further provides an endogenous protein degradation system based on the delta Trim21. The method has the characteristics of high specificity, rapidness and small module, so that the method can be used for researching various biological and disease mechanisms, including the fields of cell targeted therapy, cell mechanism exploration, genetic engineering and the like.
Owner:EAST CHINA NORMAL UNIV

Bispecific stealth lipid nanoparticle compositions for cell targeting

PCT designated stage expiredWO2025090417A1Organic active ingredientsPowder deliveryNanoparticleCell type
The present disclosure provides bispecific stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., hematopoietic stem cells, to modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.
Owner:GENERATION BIO CO

Enhanced regulatory t cells and methods of use thereof

Methods and compositions for treating fibrosis (e.g., cardiac fibrosis), or other conditions associated with inflammation and / or fibrosis are provided. Methods can include administering a nucleic acid encoding a sialic acid-binding immunoglobulin-type lectin 9 (Siglec-9) protein to a subject in need of fibrosis treatment, where the Siglec-9 protein is expressed by the nucleic acid in regulatory T (Treg) cells in the subject. Methods and compositions can include Treg cells that overexpress Siglec-9 to enhance the ability of Treg cells to target cells expressing amine oxidase, copper containing 3 (AOC3), including fibroblasts or myofibroblasts. In some embodiments, the enhanced Treg cells are targeted to myofibroblasts (e.g., cardiac myofibroblasts) with elevated expression of fibrotic genes.
Owner:CEDARS SINAI MEDICAL CENT

Conjugated oligonucleotides and uses thereof

Provided herein are oligomeric compounds comprising a bicycle ligand and a modified oligonucleotide. This compound may comprise a bicycle ligand as the cell-targeting moiety, and may also comprise a conjugate linker to connect the bicycle ligand and modified oligonucleotide. This compound may be used in conjunction with a pharmaceutically acceptable salt.
Owner:BICYCLETX LTD

Specific cell-targeted hybrid nano delivery carrier as well as preparation method and application thereof

The invention discloses a specific cell targeted hybrid nano-delivery carrier and a preparation method and application thereof, and aims to solve the problems of insufficient specificity, off-target risk, low delivery efficiency and the like of an existing drug delivery system. And a bionic hybrid nano delivery platform with a natural targeting function and high drug loading capacity is constructed. The vector retains key receptor molecules and signal markers on a source cell membrane, and can actively identify and target corresponding cells; meanwhile, due to the introduction of the lipidosome, the yield and stability of the material are remarkably improved, and the immune clearance rate is reduced. Experimental results show that the nano-carrier shows good targeting and biocompatibility in various disease models, and has wide clinical application prospects in the aspects of tumor treatment, tissue repair, inflammation control, targeted imaging and the like.
Owner:THE AFFILIATED SIR RUN RUN SHAW HOSPITAL OF SCHOOL OF MEDICINE ZHEJIANG UNIV

Efficient vascular endothelial cell targeting vesicle system as well as preparation method and application thereof

The invention belongs to the technical field of biological medicine, and discloses a high-efficiency vascular endothelial cell targeting vesicle system, which is prepared from hemangioma stem cell derived exosome HemSCs-Exos and bone marrow mesenchymal stem cell derived apoptotic small body BMSCs-ABs, and is characterized in that the endothelial cell targeting vesicle system is prepared from the hemangioma stem cell derived exosome HemSCs-Exos and the bone marrow mesenchymal stem cell derived apoptotic small body BMSCs-ABs; meanwhile, the invention further discloses a preparation method of the vesicle system and application of the vesicle system in promoting proliferation and migration of endothelial cells. Different from existing targeting modification, the ingenious targeting relationship between the BMSCs-ABs and the endothelial cells belongs to non-special modification combination, and is simple and efficient; the fusion between the double EVs has the characteristic of realizing '1 + 1gt, 2', not only retains the treatment components of the HemSCs-Exos and the BMSCs-ABs, but also the fused eHEs has remarkable cell specificity distribution, and the fusion mode is simple and stable.
Owner:THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV

NRP1-targeting single-chain antibody, CAR-T cell and application of CAR-T cell in fibrosis treatment

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to a single-chain antibody targeting NRP1, a CAR-T cell and application of the single-chain antibody and the CAR-T cell in fibrosis treatment. Four types of high-affinity single-chain antibodies targeting mouse NRP1 antigens are obtained by immunizing mice, the single-chain antibodies are applied to second-generation CAR, T cells of mouse spleen sources are infected after virus packaging, and CAR-T cells are constructed. The CAR-T cells of the targeted NRP1 can be used for effectively killing NRP1 positive cells. In-vivo experiments show that the CAR-T cells can inhibit the growth of NRP1 positive tumor cells. The CAR-T cell can improve the mouse liver fibrosis condition, collagen in the mouse liver is reduced through treatment, and the molecular level of fibrosis markers SMA and NRP1 is reduced, it is indicated that the CAR-T cell recognizes and eliminates activated HSCs through targeting NRP1, and the fibrosis degree is reduced.
Owner:SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY (SHANDONG PROVINCIAL HOSPITAL)

Natural killer cells for chordoma therapy

Provided herein are methods and compositions for treating chordoma by preferentially targeting cancer stem cells than non-cancer stem cells in chordoma to effectively treat chordoma. In some embodiments, the chordoma tumors cells (preferentially the cancer stem cells in chordoma) are targeted by modified NK-92 cells (i.e., haNK® cells) that express CARs that comprise means for binding to the PD-L1 and another tumor-specific antigen (e.g., EGFR). In some embodiments, the chordoma tumor cells are targeted by using NK cells in combination with a means for binding to means for binding to the PD-L1 and / or a means for binding another tumor antigen (e.g., EGFR). Each of the treatment methods disclosed above may be implemented prior to, and / or concurrent with radio- and / or chemotherapy, and / or may be employed with immune therapy as is discussed in more detail below.
Owner:IMMUNITYBIO INC

DC (dendritic cell) targeting mRNA (messenger ribonucleic acid) delivery system and preparation method thereof

The invention belongs to the technical field of biological medicine, and particularly relates to an mRNA delivery system of a targeted DC cell and a preparation method of the mRNA delivery system. Two molecules of mannose and guanidinoacetic acid are innovatively grafted to a cyclodextrin structure of polyrotaxane through triethylene tetramine, the grafted mannose has a DC cell targeting effect, and guanidyl in guanidinoacetic acid has a potential cell penetrating effect. Experimental results show that when the two are grafted to the cyclodextrin structure of polyrotaxane at the same time, the targeting accuracy and delivery efficiency of the delivery system to DC cells can be synergistically improved. The prepared mRNA delivery system of the targeting DC cell not only enriches the research scope of a nucleic acid delivery system, but also provides powerful technical support for the biological medicine field such as tumor treatment.
Owner:WEITUYING (TIANJIN) BIOTECHNOLOGY CO LTD +1

Surface modified hepatocyte targeting molecule-based ferroferric oxide nanoparticle as nuclear magnetic resonance imaging contrast agent as well as preparation method and application of surface modified hepatocyte targeting molecule-based ferroferric oxide nanoparticle as nuclear magnetic resonance imaging contrast agent

The invention discloses a preparation method of a nuclear magnetic resonance imaging contrast agent based on surface hepatocyte targeting molecule modification ferroferric oxide nanoparticles, which comprises the following steps: synthesizing ferroferric oxide nanoparticles (Fe3O4 NPs) by a thermal decomposition method, and connecting the Fe3O4 NPs with a ligand dopamine-PEG2000-EOB carrying hepatocyte targeting molecules by a ligand exchange method to obtain the nuclear magnetic resonance imaging contrast agent. The nanoparticles Fe3O4-EOB-PEG capable of carrying out selective T2 nuclear magnetic resonance imaging on the hepatocytes are formed. The method is simple and easy to operate, the controllability of the preparation process is high, the biocompatibility of the obtained product is good, T2 signals of hepatocytes can be remarkably improved, the good early diagnosis effect on liver tumors is achieved, and wide application prospects are achieved.
Owner:ZHONGNAN HOSPITAL OF WUHAN UNIV

Reagent and method for high-throughput single-cell targeted sequencing

The present invention provides a method for single-cell analysis, comprising dividing a cell and a bead attached with multiple barcoded oligonucleotides into a partition. Each of the multiple barcoded oligonucleotides may contain a cell barcode and a unique molecular identifier (UMI), and binds to a poly A sequence of mRNA by means of a polyT sequence at the end of the oligonucleotide to complete the capture of mRNA. First-strand and second-strand synthesis of mRNA are completed by reverse transcription and PCR amplification, respectively. One part of cDNA is used to construct a transcriptome sequencing library, and the other part of cDNA is circularized to form circular double-stranded cDNA, which is used as a template to specifically enrich a target gene. Since the cell barcode information carried by one part of cDNA matches that carried by the other part of cDNA, the information of the expression profile of the cell and the information of paired target gene sequences can be obtained by performing sequencing followed by performing Barcode sequence matching.
Owner:SINGLERON NANJING BIOTECHNOLOGIES LTD

Compositions and uses of vasoactive intestinal peptide (VIP) antagonists

This disclosure relates to VIP antagonist for uses in managing the treatment or prevention of cancer and viral infections. In certain embodiments, this disclosure relates to chimeric variants of VIP antagonists, as peptides disclosed herein, and pharmaceutical composition comprising the same. In certain embodiments, this disclosure contemplates methods of stimulating immune cells to target cancer by mixing immune cells in vitro with peptides disclosed herein and further administering an effective amount of stimulated immune cells to a subject in need of cancer treatment.
Owner:EMORY UNIVERSITY

Emulsifier for preparing Pickering emulsion, Pickering emulsion as well as preparation method and application of Pickering emulsion

The invention discloses an emulsifier for preparing a Pickering emulsion, the Pickering emulsion as well as a preparation method and application of the Pickering emulsion. The emulsifier of the Pickering emulsion is obtained by dissolving distearoyl phosphatidylcholine, cholesterol and distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 in ethanol, carrying out rotary evaporation to remove ethanol, then adding an antigen aqueous solution containing an antigen, continuing rotary evaporation to obtain liposome nanoparticles, heating the liposome nanoparticles with mannose in a water bath, and carrying out freeze drying. The Pickering emulsion is obtained by dispersing an emulsifier in water as a water phase, taking squalene as an oil phase, mixing the water phase and the oil phase, and homogenizing. The Pickering emulsion disclosed by the invention is prepared by taking antigen presenting cell targeted liposome nanoparticles as a raw material; and the antigen has excellent ion concentration characteristic, pH stability, temperature stability and storage stability, and can protect the integrity of the antigen.
Owner:SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI

Cellular targeted label delivery system

The present invention relates to an isolated cellular targeted delivery system comprising a CD45+ leukocyte cell comprising within said cell a complex of one or more iron binding proteins and / or a label as well as methods for producing such isolated cellular targeted delivery system and uses of such system for therapy diagnosis and in particular for diagnosis of cancer, particularly metastatic cancer, in particular for therapy of cancer.
Owner:CELLIS AG

Prebiotics-loaded intestinal targeting exosome as well as preparation method and application thereof

The invention discloses a prebiotic-loaded intestinal targeting exosome and a preparation method and application thereof.The preparation method comprises the steps that firstly, plasmids containing intestinal cell targeting peptide sequences are constructed through a gene editing technology, the plasmids are transfected and introduced into cells, the transfected cells are screened with antibiotics, and cell strains stably expressing intestinal cell targeting peptides are obtained; then culturing and adding prebiotics, and continuously culturing to enable the cells to take in the prebiotics and release the exosomes loaded with the prebiotics; and finally, collecting cell culture supernate, and centrifuging and resuspending for multiple times under a low-temperature condition to obtain the prebiotics-loaded intestinal targeting exosome. According to the preparation method, extraction of the exosome, loading of the prebiotics and an intestinal targeting modification process are optimized, so that the prepared intestinal targeting exosome loaded with the prebiotics can be used for remarkably improving the loading efficiency and intestinal targeting of the prebiotics and enhancing the stability of the exosome in gastrointestinal tracts; therefore, the delivery efficiency and the treatment effect of the prebiotics in the intestinal tract are improved.
Owner:SHAANXI UNIV OF SCI & TECH

Improved hyaluronic acid injection formulations for inflammation targeting and stem cell capture, and methods of making and uses thereof

The application provides an improved hyaluronic acid injection preparation for inflammation targeting and stem cell capture, a preparation method and use thereof, and belongs to the field of medicine. The injection preparation is prepared from unsaturated bond modified hyaluronic acid, stem cell targeting DNA tetrahedron and thiol modified inflammation targeting aptamer as raw materials. The injection preparation can be targeted to accumulate at an osteoarthritis site, capture mesenchymal stem cells in situ, recruit mesenchymal stem cells to the osteoarthritis site, promote differentiation of stem cells into cartilage, promote cartilage repair, play a role in treating osteoarthritis, and has a good application prospect.
Owner:SICHUAN UNIV

Compositions and methods for t cell targeted delivery of therapeutic agents

The present disclosure relates, in part, to immune cell targeted lipid nanoparticle (LNP) compositions, and methods of use thereof for in vivo delivery of nucleic acid molecules and / or therapeutic agents to a target cell. In certain embodiments, the nucleic acid molecules encode chimeric antigen receptors (CARs). In certain embodiments, the target cell is a T cell. In certain embodiments, the present disclosure relates to the use of the LNPs described herein for the treatment, prevention, and / or amelioration of diseases and / or disorders, including but not limited to cancer.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA

Stealth lipid nanoparticle compositions for cell targeting

The present disclosure provides stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., T cells, B cells, natural killer cells, to genetically modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.
Owner:GENERATION BIO CO

Method for treating rheumatoid arthritis

A method for determining if an agent is suitable for treating a Rheumatoid Arthritis (RA) patient, the method comprising determining the profile of a first, second and / or third marker panel in a sample from the patient, wherein the agent is selected from an agent that downregulates TNF mediated signalling, an agent that downregulates IL-6 mediated signalling and a B cell targeted therapy.
Owner:QUEEN MARY UNIV OF LONDON

Improved cell-targeting binding molecule

The invention relates to a therapeutic combination, comprising a first proteinaceous molecule comprising a first binding site for binding to a first epitope of a first cell-surface molecule, the first proteinaceous molecule provided with at least one saponin covalently bound to an amino-acid residue of said first proteinaceous molecule, and comprising a second pharmaceutical composition comprising a second proteinaceous molecule different from the first proteinaceous molecule, the second proteinaceous molecule comprising a second binding site for binding to a second epitope of a second cell-surface molecule different from the first cell-surface molecule, and comprising an effector moiety, wherein the second epitope is different from the first epitope. An aspect of the invention is a composition comprising the first proteinaceous molecule and the second proteinaceous molecule of the invention. The invention also relates to an antibody-drug conjugate comprising the first proteinaceous molecule of the invention and an effector moiety. An aspect of the invention relates to a pharmaceutical composition comprising the composition or the antibody-drug conjugate of the invention, and optionally further comprising a pharmaceutically acceptable excipient. The invention also relates to the therapeutic combination or the composition or the antibody-drug conjugate or the pharmaceutical composition of the invention, for use as a medicament. The invention also relates to the therapeutic combination of the invention for use in the treatment or prophylaxis of a cancer.
Owner:SAPREME TECH BV

Carrier system for realizing targeted drug delivery based on glutathione responding to microenvironment active oxygen as well as preparation method and application of carrier system

The invention discloses a carrier system for realizing targeted drug delivery based on glutathione responding to microenvironment active oxygen, a preparation method of the carrier system and an application of the carrier system in in-vivo delivery of treatment genes such as FSTL3, an inner core is a micelle formed by self-assembly of a diblock copolymer PLys-S-PPhe, and glutathione and the treatment genes are compounded on the surface of the micelle through an electrostatic adsorption effect. After the carrier system enters a focus, GSH adsorbed by a shell reacts with ROS of the focus, a microenvironment anti-oxidation treatment effect is generated, after obvious shell dissociation, strong positive electricity core 'PLys-S-PPhe' release, core release and overall surface positive electricity increase of the medicine occur, endocytosis of lesion cells in the placenta is easily promoted, and a cell targeting delivery effect of FSTL3 and other medicines is generated; according to the present invention, with the application of the compound, the focus targeting retention effect of the positive electric core is generated, the efficient distribution similar to the focus targeting in the placenta is achieved, the toxicity to the maternal body or the fetus is reduced, and the new carrier is provided for the drug for treating the diseases related to the oxidative stress in the placenta.
Owner:THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV

Endoplasmic reticulum fluorescent probe as well as preparation and application thereof

The invention relates to an endoplasmic reticulum fluorescent probe as well as preparation and application thereof, and belongs to the field of fluorescent probes and biological medicines. Comprising an antibiotic, a cell targeting polypeptide RGD and a fluorescent dye capable of generating singlet oxygen which are coupled in sequence, the cell targeting polypeptide RGD is used for targeting cells, the antibiotic is used for anchoring ribosome inlaid on an endoplasmic reticulum, and the fluorescent dye is used for fluorescence imaging and / or singlet oxygen generation. Different from a design principle that a traditional endoplasmic reticulum probe targets an endoplasmic reticulum structure by lipophilic molecules, the cell endoplasmic reticulum fluorescent probe disclosed by the invention provides a novel method for firstly targeting ribosome by small molecule affinity and then further imaging the endoplasmic reticulum through distribution of the ribosome on the endoplasmic reticulum. The invention also provides a synthesis method of the endoplasmic reticulum fluorescent probe. The probe is good in imaging effect, high in specificity and short in marking time, and singlet oxygen can be generated for photodynamic therapy.
Owner:HUAZHONG UNIV OF SCI & TECH